{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T07:54:55Z","timestamp":1772956495103,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R25DA0333211"],"award-info":[{"award-number":["R25DA0333211"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["HEV-172884"],"award-info":[{"award-number":["HEV-172884"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-153429"],"award-info":[{"award-number":["PJT-153429"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-156306"],"award-info":[{"award-number":["PJT-156306"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Health Research BC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.dadr.2025.100368","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T16:24:31Z","timestamp":1753806271000},"page":"100368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Impact of hepatitis C serostatus on health service utilization for opioid-related harms among individuals prescribed opioid agonist therapy: A longitudinal prospective cohort study"],"prefix":"10.1016","volume":"16","author":[{"given":"Paige","family":"Guyatt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenda","family":"Babe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Gayowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7406-4056","authenticated-orcid":false,"given":"Tea","family":"Rosic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7953-773X","authenticated-orcid":false,"given":"Myanca","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2413-9133","authenticated-orcid":false,"given":"Paxton","family":"Bach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3961-6008","authenticated-orcid":false,"given":"Claire","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey H.","family":"Samet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Kerkerian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Hann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna C.","family":"Dionne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1488-6055","authenticated-orcid":false,"given":"Seonaid","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab","family":"Samaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany B.","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dadr.2025.100368_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.drugpo.2009.03.004","article-title":"A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility","volume":"21","author":"Andresen","year":"2010","journal-title":"Int. J. Drug Policy"},{"issue":"4","key":"10.1016\/j.dadr.2025.100368_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/acps.13088","article-title":"Reduction in mortality risk with opioid agonist therapy: a systematic review and meta-analysis","volume":"140","author":"Bahji","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.dadr.2025.100368_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/00952990802342899","article-title":"A meta-analysis of retention in methadone maintenance by dose and dosing strategy","volume":"35","author":"Bao","year":"2009","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"8","key":"10.1016\/j.dadr.2025.100368_bib4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/01.meg.0000280175.79379.04","article-title":"Treatment for hepatitis C virus in injection drug users on opioid replacement therapy: a prospective multicentre study","volume":"19","author":"Belfiori","year":"2007","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.dadr.2025.100368_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.dld.2008.08.009","article-title":"Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone\/buprenorphine maintenance therapy","volume":"41","author":"Belfiori","year":"2009","journal-title":"Dig. Liver. Dis."},{"issue":"10","key":"10.1016\/j.dadr.2025.100368_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001885","article-title":"The Reporting of studies conducted using observational routinely-collected health data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS. Med."},{"key":"10.1016\/j.dadr.2025.100368_bib7","unstructured":"Center for Substance Abuse Treatment, 2006. Substance Abuse: Clinical Issues in Intensive Outpatient Treatment. Appendix B. Urine Collection and Testing Procedures and Alternative Methods for Monitoring Drug Use. \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64092\u3009. (accessed 7 July 2025)."},{"key":"10.1016\/j.dadr.2025.100368_bib8","article-title":"Health service utilization, substance use treatment response, and death in patients with opioid use disorder and comorbid hepatitis C findings from prospective cohort study with administrative database linkage","volume":"167","author":"Dennis","year":"2024","journal-title":"J. Subst. Use Abus. Treat."},{"issue":"4","key":"10.1016\/j.dadr.2025.100368_bib9","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1097\/ADM.0000000000000937","article-title":"Sex-specific risk factors and health disparity among hepatitis C positive patients receiving pharmacotherapy for opioid use disorder: findings from a propensity matched analysis","volume":"16","author":"Dennis","year":"2022","journal-title":"J. Addic. Med."},{"issue":"4","key":"10.1016\/j.dadr.2025.100368_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/10550880903183042","article-title":"High dose versus moderate dose methadone maintenance: is there a better outcome?","volume":"28","author":"Fareed","year":"2009","journal-title":"J. Addic Dis."},{"issue":"18","key":"10.1016\/j.dadr.2025.100368_bib11","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMra042823","article-title":"Bacterial infections in drug users","volume":"353","author":"Gordon","year":"2005","journal-title":"N. Eng. J. Med."},{"issue":"5","key":"10.1016\/j.dadr.2025.100368_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/ADM.0000000000001189","article-title":"Evidence on buprenorphine dose limits: a review","volume":"17","author":"Grande","year":"2023","journal-title":"J. Addic Med."},{"issue":"8","key":"10.1016\/j.dadr.2025.100368_bib13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamapsychiatry.2018.0611","article-title":"Making the opioid public health emergency effective","volume":"75","author":"Haffajee","year":"2018","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.dadr.2025.100368_bib14","series-title":"Best practices: Concurrent mental health and substance use disorders","author":"Health Canada","year":"2001"},{"key":"10.1016\/j.dadr.2025.100368_bib15","series-title":"Federal action on the overdose crisis","author":"Health Canada","year":"2024"},{"issue":"2","key":"10.1016\/j.dadr.2025.100368_bib16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/0022042616679829","article-title":"A cost-benefit analysis of a potential supervised injection facility in San Francisco, California, USA","volume":"47","author":"Irwin","year":"2016","journal-title":"J. Drug Issues"},{"issue":"1","key":"10.1016\/j.dadr.2025.100368_bib17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12954-017-0154-1","article-title":"Supervised injection facilities in Canada: past, present, and future","volume":"14","author":"Kerr","year":"2017","journal-title":"Harm Reduct. J."},{"issue":"4","key":"10.1016\/j.dadr.2025.100368_bib18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3111\/13696998.2015.1127252","article-title":"Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C","volume":"19","author":"LaMori","year":"2016","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.dadr.2025.100368_bib19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/1471-2458-10-327","article-title":"Determinants of hospitalization for a cutaneous injection-related infection among injection drug users: a cohort study","volume":"10","author":"Lloyd-Smith","year":"2010","journal-title":"B. M. C. Public Health"},{"issue":"12","key":"10.1016\/j.dadr.2025.100368_bib20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.14745\/ccdr.v47i12a01","article-title":"The hepatitis C epidemic in Canada: an overview of recent trends in surveillance, injection drug use, harm reduction and treatment","volume":"47","author":"Louren\u00e7o","year":"2021","journal-title":"Can. Commun. Dis. Rep"},{"issue":"12","key":"10.1016\/j.dadr.2025.100368_bib21","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1046\/j.1360-0443.1998.9312185711.x","article-title":"The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome","volume":"93","author":"Marsden","year":"1998","journal-title":"Addiction"},{"issue":"9651","key":"10.1016\/j.dadr.2025.100368_bib22","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0140-6736(08)61311-2","article-title":"Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review","volume":"372","author":"Mathers","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.dadr.2025.100368_bib23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.20279","article-title":"A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance","volume":"40","author":"Mauss","year":"2004","journal-title":"Hepatol"},{"issue":"10","key":"10.1016\/j.dadr.2025.100368_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003351","article-title":"Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility","volume":"3","author":"Milloy","year":"2008","journal-title":"PLoS. One"},{"key":"10.1016\/j.dadr.2025.100368_bib25","unstructured":"National Institute on Drugs, 2024. Drug Overdose and Death Rates. \u3008https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates\u3009. (accessed 20 May 2024)."},{"issue":"9","key":"10.1016\/j.dadr.2025.100368_bib26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/apc.2012.0170","article-title":"Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection","volume":"26","author":"Norton","year":"2012","journal-title":"AIDS Patient Care STD"},{"issue":"2","key":"10.1016\/j.dadr.2025.100368_bib27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11904-018-0390-3","article-title":"The syndemic of opioid misuse, overdose, HCV, and HIV: structural-level causes and interventions","volume":"15","author":"Perlman","year":"2018","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"4","key":"10.1016\/j.dadr.2025.100368_bib28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jsat.2010.07.009","article-title":"The SUMMIT Trial: a field comparison of buprenorphine versus methadone maintenance treatment","volume":"39","author":"Pinto","year":"2010","journal-title":"J. Subst. Abus. Treat."},{"issue":"6","key":"10.1016\/j.dadr.2025.100368_bib29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3390\/pathogens9060432","article-title":"Systematic review and meta-analysis of global prevalence of HBsAg and HIV and HCV antibodies among people who inject drugs and female sex workers","volume":"9","author":"Rashti","year":"2020","journal-title":"Pathogens"},{"issue":"7","key":"10.1016\/j.dadr.2025.100368_bib30","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/cid\/ciaa105","article-title":"Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs","volume":"71","author":"Rosenthal","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.dadr.2025.100368_bib31","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2147\/NDT.S66234","article-title":"Genetic influence on methadone treatment outcomes in patients undergoing methadone maintenance treatment for opioid addiction: a pilot study","volume":"10","author":"Samaan","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"4","key":"10.1016\/j.dadr.2025.100368_bib32","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/hep.21791","article-title":"Hepatitis C treatment in \u201cdifficult-to-treat\u201d psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects","volume":"46","author":"Schaefer","year":"2007","journal-title":"Hepatol"},{"issue":"4","key":"10.1016\/j.dadr.2025.100368_bib33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1360-0443.2009.02509.x","article-title":"Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy","volume":"104","author":"Sch\u00e4fer","year":"2009","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.dadr.2025.100368_bib34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13011-018-0187-9","article-title":"Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: a cross-sectional study","volume":"14","author":"Strada","year":"2019","journal-title":"Subst. Abus. Treat. Prev. Policy"},{"issue":"3","key":"10.1016\/j.dadr.2025.100368_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jsat.2005.06.002","article-title":"The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone","volume":"29","author":"Sylvestre","year":"2005","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.dadr.2025.100368_bib36","series-title":"Report and recommendations on the opioid crisis in Canada","author":"The Standing Committee on Health","year":"2016"},{"issue":"8","key":"10.1016\/j.dadr.2025.100368_bib37","doi-asserted-by":"crossref","first-page":"W-163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration","volume":"147","author":"Vandenbroucke","year":"2007","journal-title":"Ann. Intern. Med."},{"issue":"17","key":"10.1016\/j.dadr.2025.100368_bib38","first-page":"453","article-title":"Increases in hepatitis C virus infection related to injection drug use among persons aged \u226430 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. M.M.W.R. Morb. Mortal","volume":"64","author":"Zibbell","year":"2015","journal-title":"Wkly. Rep."}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724625000514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724625000514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:10:49Z","timestamp":1772921449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724625000514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"alternative-id":["S2772724625000514"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2025.100368","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of hepatitis C serostatus on health service utilization for opioid-related harms among individuals prescribed opioid agonist therapy: A longitudinal prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2025.100368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100368"}}